Curanex Pharmaceuticals Inc (CURX) stock
CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.70+0.07 (+1.40%)
Close on Nov 17, 2026Market cap $7.37MP/E –Yield –
Curanex Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Curanex Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.11M. For fiscal 2025 it was $2.99M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.95M | +188.2% |
| Q2 FY2026 | Jun 30, 2026 | $2.59M | – |
| Q1 FY2026 | Mar 31, 2026 | $2.26M | – |
| Q4 FY2025 | Dec 31, 2025 | $2.31M | – |
| Q3 FY2025 | Sep 30, 2025 | $677.47K | – |
See a number that looks wrong?